Lexeo Net Income From Continuing Ops from 2010 to 2024

LXEO Stock   8.23  0.40  5.11%   
Lexeo Therapeutics, Net Loss yearly trend continues to be very stable with very little volatility. Net Loss is likely to drop to about -69.7 M. During the period from 2010 to 2024, Lexeo Therapeutics, Net Loss quarterly data regression pattern had range of 64.6 M and standard deviation of  26,088,585. View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-66.4 M
Current Value
-69.7 M
Quarterly Volatility
26.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Lexeo Therapeutics, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lexeo Therapeutics,'s main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 2.8 M or Depreciation And Amortization of 1.9 M, as well as many indicators such as Price To Sales Ratio of 369, Dividend Yield of 0.0 or PTB Ratio of 3.31. Lexeo financial statements analysis is a perfect complement when working with Lexeo Therapeutics, Valuation or Volatility modules.
  
Check out the analysis of Lexeo Therapeutics, Correlation against competitors.

Latest Lexeo Therapeutics,'s Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Lexeo Therapeutics, Common over the last few years. It is Lexeo Therapeutics,'s Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lexeo Therapeutics,'s overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

Lexeo Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(20,179,158)
Coefficient Of Variation(129.28)
Mean Deviation22,038,676
Median(5,152,788)
Standard Deviation26,088,585
Sample Variance680.6T
Range64.6M
R-Value(0.78)
Mean Square Error288.6T
R-Squared0.61
Significance0.0006
Slope(4,542,398)
Total Sum of Squares9528.6T

Lexeo Net Income From Continuing Ops History

2024-69.7 M
2023-66.4 M
2022-59.3 M
2021-50.6 M

About Lexeo Therapeutics, Financial Statements

Lexeo Therapeutics, investors utilize fundamental indicators, such as Net Income From Continuing Ops, to predict how Lexeo Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Loss-66.4 M-69.7 M

Pair Trading with Lexeo Therapeutics,

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lexeo Therapeutics, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lexeo Therapeutics, will appreciate offsetting losses from the drop in the long position's value.

Moving against Lexeo Stock

  0.8BMY Bristol Myers Squibb Sell-off TrendPairCorr
  0.69GILD Gilead SciencesPairCorr
  0.66BHC Bausch Health CompaniesPairCorr
  0.65ESPR Esperion Therapeutics Buyout TrendPairCorr
  0.61WAT WatersPairCorr
The ability to find closely correlated positions to Lexeo Therapeutics, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lexeo Therapeutics, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lexeo Therapeutics, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lexeo Therapeutics, Common to buy it.
The correlation of Lexeo Therapeutics, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lexeo Therapeutics, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lexeo Therapeutics, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lexeo Therapeutics, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Lexeo Therapeutics, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lexeo Therapeutics,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lexeo Therapeutics, Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lexeo Therapeutics, Common Stock:
Check out the analysis of Lexeo Therapeutics, Correlation against competitors.
You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lexeo Therapeutics,. If investors know Lexeo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lexeo Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(12.53)
Return On Assets
(0.40)
Return On Equity
(0.75)
The market value of Lexeo Therapeutics, is measured differently than its book value, which is the value of Lexeo that is recorded on the company's balance sheet. Investors also form their own opinion of Lexeo Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Lexeo Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lexeo Therapeutics,'s market value can be influenced by many factors that don't directly affect Lexeo Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lexeo Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Lexeo Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lexeo Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.